Obesity medications: What does the future look like?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 5, 2015, Pages 360-366

  Butsch, W Scott ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

beloranib; liraglutide; lorcaserin; naltrexone bupropion; obesity medications; phentermine topiramate

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; DRUG COMBINATION; NEW DRUG;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONSTIPATION; DIZZINESS; DRUG HALF LIFE; ENERGY EXPENDITURE; HEADACHE; HUMAN; LIFESTYLE MODIFICATION; NAUSEA; NEGATIVE FEEDBACK; OBESITY; REVIEW; RHINOPHARYNGITIS; STOMACH EMPTYING; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; DEVICE APPROVAL; DRUG COMBINATION; DRUG EFFECTS; ENERGY METABOLISM; FOOD AND DRUG ADMINISTRATION; LIFESTYLE; UNITED STATES;

ANTI-OBESITY AGENTS; DEVICE APPROVAL; DRUG COMBINATIONS; DRUGS, INVESTIGATIONAL; ENERGY METABOLISM; HUMANS; LIFE STYLE; OBESITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84958961099     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000192     Document Type: Review

References (33)

1. Yang L, Colditz GA. Prevalence of overweight and obesity in the United States, 2007-2012. J Am Med Assoc Intern Med [Published online 22 June 2015].
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. J Am Med Assoc 2012; 307:491-497.
3. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-Analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107:1755-1767.
4. Dansinger ML, Tatsioni A, Wong JB, et al. Meta-Analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007; 147:41-50.
5. Mann T, Tomiyama AJ, Westling E, et al. Medicare?s search for effective obesity treatments: diets are not the answer. Am Psychol 2007; 62:220-233.
6. FDA Press Release on Contrave 9.10.2014. http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm413896.htm. [Accessed 2 May 2015]
7. Goldstein MG. Bupropion sustained release and smoking cessation. J Clin Psychiatry 1998; 59:66-72.
8. Li Z. Meta-Analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532-546.
9. Malcolm R, Oneil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes 1985; 9:347-353.
10. Greenway FL, Whitehouse MJ, Guttaduria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009; 17:30-39.
11. Greenway FL, Fujioka K, Plodkowski RA, et al., COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376:595-605.
12. Apovian CM, Aronne L, Rubino D, et al., COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013; 21:935-943.
13. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011; 19:110-120.
14. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustainedrelease/ bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022-4029.
15. Ruede-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013; 9:467-478.
16. Orexigen Press Release on LIGHT Study 5.12.2015. http://ir.orexigen.com / phoenix.zhtml?c?207034&?irol-newsArticle&ID?2047312. [Accessed 7 June 2015] Because of the termination of this study, determination of the safety and long-Term cardiovascular adverse outcomes of naltrexone/bupropion will be delayed.
17. FDA Press Release on Saxenda 12.23.2014. http://www.fda.gov/NewsE vents/Newsroom/PressAnnouncements/ucm427913.htm. [Accessed 2 May 2015]
18. Bray GA. Medical treatment of obesity: the past, present and the future. Best Pract Res Clin Gastr 2014; 28:665-684.
19. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-Daily human GLP-1 analog, liraglutide. Int J Obes 2012; 36:843-854.
20. Wadden TA, Hollander P, Klien S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-Diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes 2013; 37:1443-1451.
21. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0mg liraglutide in weight management. N Engl J Med 2015; 373:11-22.
22. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102:2836-2841.
23. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin forOverweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363:245-256.
24. Fidler MC, Sanchez M, Raether B, et al. A One-year randomized trial of Lorcaserin for weight loss in obese and overweight adults: The BLOSSOM Trial. J Clin Endocrinol Metab 2011; 96:3067-3077.
25. Oneil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of Lorcaserin for weight loss in Type 2 diabetes mellitus: The Bloom-DM Study. Obesity 2012; 20:1426-1436.
26. Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res 2011; 95:189-199.
27. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012; 20:330-342.
28. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-Dose, controlledrelease, phentermine plus topiramate combination on weight and associated co-morbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341-1352.
29. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297-308.
30. Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diab Obes Metab 2015; 17:566-572.
31. Yanovski SZ, Yanovski JA. Long-Term drug treatment for obesity: a systematic and clinical review. J Am Med Assoc 2014; 311:74-86.
32. Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin N Am 2010; 39:69-79.
33. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100:342-362.